Export financials
InMode Ltd. (INMD)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.

InMode Ltd. Income Statement 2025-2011 | INMD
Brief overview of financial performance at InMode Ltd.
The comparison covers a five-year financial horizon. InMode Ltd. reported revenue of 206 million dollars in 2020 and 370 million dollars by 2025. Across the full period, sales moved by +79.8%; the average annual rate was 12.4%. Top-line growth remained consistently strong over the period.
At the gross-profit level, the result moved from $175 million to $291 million, a change of +66%. Direct costs outpaced revenue, limiting the benefit of changes in sales. At the margin level, the figure shifted from 85% to 78.5%. The margin decline reflects a less favorable sales-and-cost structure.
The operating result measured by EBITDA moved from $73.3 million to $86.1 million, or +17.5%. EBITDA underperformed the top-line trend. At the operating-margin level, the figure shifted from 35.5% to 23.2%. The margin contraction indicates weaker operating efficiency.
The net result moved from 75 million dollars to 93.8 million dollars, or +25.1%. There was no meaningful strengthening in net profitability.
Market value was 2.1 billion dollars at the start and 928 million dollars at the end. The market is not yet fully reflecting the fundamental progress.
Financial takeaway
The current trajectory does not yet confirm a sustainable recovery. The strongest signals are sales growth and a stronger final result. The weaker side of the profile includes a declining EBITDA margin, a weaker market valuation and pressure from direct costs. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement InMode Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
928 M | 1.43 B | 1.78 B | 3.11 B | 3.93 B | 2.12 B | 1.27 B | 1 B | 991 M | - | - | - | - | - | - |
Shares |
64.6 M | 79.3 M | 83.5 M | 82.5 M | 81.4 M | 72.1 M | 58.5 M | 26.6 M | 26.3 M | - | - | - | - | - | - |
Historical Prices |
14.4 | 18.1 | 21.4 | 37.7 | 48.2 | 29.4 | 21.7 | - | - | - | - | - | - | - | - |
Net Income |
93.8 M | 181 M | 198 M | 162 M | 165 M | 75 M | 61.1 M | 22.4 M | 8.82 M | - | - | - | - | - | - |
Revenue |
370 M | 395 M | 492 M | 454 M | 358 M | 206 M | 156 M | 100 M | 53.5 M | - | - | - | - | - | - |
Cost of Revenue |
79.5 M | 77.8 M | 80.7 M | 73.5 M | 53.6 M | 30.8 M | 20.2 M | 15.1 M | 9.05 M | - | - | - | - | - | - |
Gross Profit |
291 M | 317 M | 411 M | 381 M | 304 M | 175 M | 136 M | 85.1 M | 44.4 M | - | - | - | - | - | - |
Operating Income |
85.4 M | 113 M | 196 M | 198 M | 167 M | 72.8 M | 59.6 M | 23.5 M | 8.95 M | - | - | - | - | - | - |
Interest Expense |
- | - | 4.71 M | 1.21 M | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
86.1 M | 113 M | 196 M | 199 M | 168 M | 73.3 M | 59.9 M | 23.7 M | 9.15 M | - | - | - | - | - | - |
Operating Expenses |
206 M | 205 M | 216 M | 183 M | 136 M | 102 M | 76.5 M | 53.6 M | 35.5 M | - | - | - | - | - | - |
General and Administrative Expenses |
11.7 M | 10 M | 9.23 M | 9.93 M | 8.41 M | 6.42 M | 70.8 M | 49.4 M | 4.36 M | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Income Statement InMode Ltd.
| 2025-Q4 | 2024-Q4 | 2023-Q4 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
64.6 M | 79.3 M | 83.5 M | - | - | - | - | 83 M | - | - | - | 75.6 M | - | - | - | 32.8 M | - | - | - | 26.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
93.8 M | 181 M | 198 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
370 M | 395 M | 492 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
79.5 M | 77.8 M | 80.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
291 M | 317 M | 411 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
85.4 M | 113 M | 196 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
- | - | 4.71 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
86.1 M | 113 M | 196 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
206 M | 205 M | 216 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
11.7 M | 10 M | 9.23 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company InMode Ltd. (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical devices industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Conformis
CFMS
|
- | - | $ 16.4 M | ||
|
Bruker Corporation
BRKR
|
$ 64.0 | 7.26 % | $ 9.72 B | ||
|
Boston Scientific Corporation
BSX
|
$ 44.68 | 0.06 % | $ 66.1 B | ||
|
Cognyte Software Ltd.
CGNT
|
$ 8.7 | 0.06 % | $ 634 M | ||
|
ClearPoint Neuro
CLPT
|
$ 14.61 | 13.03 % | $ 414 M | ||
|
CONMED Corporation
CNMD
|
$ 45.18 | 3.31 % | $ 1.4 B | ||
|
Cytosorbents Corporation
CTSO
|
$ 4.3 | 1.63 % | $ 268 M | ||
|
Eargo
EAR
|
- | - | $ 10.2 M | ||
|
Delcath Systems
DCTH
|
$ 16.08 | 0.75 % | $ 576 M | ||
|
Medigus Ltd.
MDGS
|
- | 10.28 % | $ 55.5 M | ||
|
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | ||
|
Electromed
ELMD
|
$ 27.86 | 1.05 % | $ 230 M | ||
|
Establishment Labs Holdings
ESTA
|
$ 65.58 | 3.69 % | $ 1.94 B | ||
|
Edwards Lifesciences Corporation
EW
|
$ 85.73 | 0.32 % | $ 50.1 B | ||
|
Nemaura Medical
NMRD
|
- | -17.8 % | $ 2.74 M | ||
|
AdaptHealth Corp.
AHCO
|
$ 5.57 | 0.43 % | $ 753 M | ||
|
Helius Medical Technologies
HSDT
|
$ 2.9 | 0.69 % | $ 63.9 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
$ 15.88 | 2.25 % | $ 1.22 B | ||
|
Inogen
INGN
|
$ 5.23 | 2.75 % | $ 139 M | ||
|
Inspire Medical Systems
INSP
|
$ 68.81 | 0.59 % | $ 2.02 B | ||
|
Neovasc
NVCN
|
- | - | $ 111 M | ||
|
IRIDEX Corporation
IRIX
|
$ 0.63 | 2.51 % | $ 10.7 M | ||
|
IRadimed Corporation
IRMD
|
$ 85.2 | 0.08 % | $ 1.08 B | ||
|
AxoGen
AXGN
|
$ 43.32 | 0.48 % | $ 1.99 B | ||
|
Align Technology
ALGN
|
$ 145.63 | 4.36 % | $ 10.6 B | ||
|
LENSAR
LNSR
|
$ 7.08 | 0.28 % | $ 84.7 M | ||
|
Sientra
SIEN
|
- | -16.59 % | $ 10.3 M | ||
|
Silk Road Medical, Inc
SILK
|
- | - | $ 1.07 B | ||
|
Medtronic PLC
MDT
|
$ 88.51 | 0.32 % | $ 113 B | ||
|
MiMedx Group
MDXG
|
$ 4.71 | 0.1 % | $ 696 M | ||
|
Surgalign Holdings
SRGA
|
- | -32.98 % | $ 1.68 M | ||
|
ShockWave Medical
SWAV
|
- | - | $ 12.3 B | ||
|
Myomo
MYO
|
$ 1.67 | 1.83 % | $ 69.9 M | ||
|
Nano-X Imaging Ltd.
NNOX
|
$ 0.66 | 0.45 % | $ 42.8 M | ||
|
InspireMD
NSPR
|
$ 0.7 | 0.37 % | $ 45 M | ||
|
Orthofix Medical
OFIX
|
$ 9.16 | 0.11 % | $ 363 M | ||
|
Outset Medical
OM
|
$ 3.13 | 1.29 % | $ 47.6 K | ||
|
Insulet Corporation
PODD
|
$ 135.78 | 0.01 % | $ 9.55 B | ||
|
Profound Medical Corp.
PROF
|
$ 5.6 | 1.66 % | $ 169 M | ||
|
Titan Medical
TMDI
|
- | -26.32 % | $ 19.6 M | ||
|
Quanterix Corporation
QTRX
|
$ 3.18 | 0.63 % | $ 136 M | ||
|
Natus Medical Incorporated
NTUS
|
- | 1.94 % | $ 1.05 B | ||
|
AVITA Medical
RCEL
|
$ 11.58 | 5.75 % | $ 323 M | ||
|
Cardiovascular Systems
CSII
|
- | 0.15 % | $ 844 M | ||
|
Apyx Medical Corporation
APYX
|
$ 2.83 | 1.37 % | $ 116 M | ||
|
Sintx Technologies
SINT
|
$ 1.87 | 5.06 % | $ 5.19 M | ||
|
Accuray Incorporated
ARAY
|
$ 0.22 | 0.4 % | $ 27 M | ||
|
Smith & Nephew plc
SNN
|
$ 26.68 | 0.02 % | $ 23.1 B | ||
|
Inari Medical
NARI
|
- | - | $ 4.23 B |